Literature DB >> 28246276

Interplay between Immune Checkpoint Proteins and Cellular Metabolism.

Sangbin Lim1, Joshua B Phillips1, Luciana Madeira da Silva1, Ming Zhou2, Oystein Fodstad3, Laurie B Owen4, Ming Tan4.   

Abstract

With the recent successes in immuno-oncology, renewed interest in the role of immune checkpoint modulators, such as the B7 family proteins, has escalated. The immune checkpoint proteins play a crucial role in the regulation of cellular immunity; however, their contribution to other aspects of cancer biology remains unclear. Accumulating evidence indicate that immune checkpoint proteins can regulate metabolic energetics of the tumor, the tumor microenvironment, and the tumor-specific immune response, leading to metabolic reprogramming of both malignant cells and immune cells involved in mounting and sustaining this response. Immune cell metabolism impacts the activation status of immune cells and ultimately the immune response in cancer. Tumor cells may deplete nutrients that immune cells require for optimal generation, expansion, and function. They may also generate toxic metabolites in the microenvironment or induce conserved inhibitory pathways that impair immune function and thus inhibit antitumor responses. In this review, we will discuss how cancer cells with altered expression of immune checkpoint proteins can potently inhibit immune function through the alteration of cellular and microenvironmental metabolism, providing a new perspective on the interplay between these pathways and offering a potential therapeutic intervention strategy in the treatment of malignant disease. Cancer Res; 77(6); 1245-9. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28246276      PMCID: PMC5354977          DOI: 10.1158/0008-5472.CAN-16-1647

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

Authors:  Ivraym B Barsoum; Chelsea A Smallwood; D Robert Siemens; Charles H Graham
Journal:  Cancer Res       Date:  2013-12-13       Impact factor: 12.701

Review 2.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 3.  Targeting T cell metabolism for therapy.

Authors:  David O'Sullivan; Erika L Pearce
Journal:  Trends Immunol       Date:  2015-01-15       Impact factor: 16.687

4.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

5.  Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α.

Authors:  Sangbin Lim; Hao Liu; Luciana Madeira da Silva; Ritu Arora; Zixing Liu; Joshua B Phillips; David C Schmitt; Tung Vu; Steven McClellan; Yifeng Lin; Wensheng Lin; Gary A Piazza; Oystein Fodstad; Ming Tan
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

6.  Anergic T cells are metabolically anergic.

Authors:  Yan Zheng; Greg M Delgoffe; Christian F Meyer; Waipan Chan; Jonathan D Powell
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

Review 7.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2012-10-25       Impact factor: 16.687

8.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin.

Authors:  Rajesh R Rao; Qingsheng Li; Kunle Odunsi; Protul A Shrikant
Journal:  Immunity       Date:  2010-01-07       Impact factor: 31.745

Review 9.  The B7 family of immune-regulatory ligands.

Authors:  Mary Collins; Vincent Ling; Beatriz M Carreno
Journal:  Genome Biol       Date:  2005-05-31       Impact factor: 13.583

10.  Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c.

Authors:  Allyson E Vaughn; Mohanish Deshmukh
Journal:  Nat Cell Biol       Date:  2008-11-23       Impact factor: 28.824

View more
  28 in total

1.  BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.

Authors:  Guillaume P Andrieu; Jordan S Shafran; Charlotte L Smith; Anna C Belkina; Allison N Casey; Naser Jafari; Gerald V Denis
Journal:  Cancer Lett       Date:  2019-08-29       Impact factor: 8.679

Review 2.  Amino Acids and Their Transporters in T Cell Immunity and Cancer Therapy.

Authors:  Weimin Wang; Weiping Zou
Journal:  Mol Cell       Date:  2020-09-29       Impact factor: 17.970

Review 3.  Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.

Authors:  Antian Gao; Xiao Pan; Xudong Yang; Zitong Lin
Journal:  Invest New Drugs       Date:  2021-02-16       Impact factor: 3.850

4.  Immunological Feature and Transcriptional Signaling of Ly6C Monocyte Subsets From Transcriptome Analysis in Control and Hyperhomocysteinemic Mice.

Authors:  Pingping Yang; Lu Liu; Lizhe Sun; Pu Fang; Nathaniel Snyder; Jason Saredy; Yong Ji; Wen Shen; Xuebin Qin; Qinghua Wu; Xiaofeng Yang; Hong Wang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 5.  Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy.

Authors:  Yu-Gui Zhang; Jiang-Tao Niu; Hong-Wei Wu; Xin-Lei Si; Shu-Juan Zhang; Dong-Hui Li; Tian-Tian Bian; Yue-Feng Li; Xing-Ke Yan
Journal:  Anal Cell Pathol (Amst)       Date:  2021-06-05       Impact factor: 2.916

Review 6.  Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.

Authors:  Soumaya Kouidhi; Farhat Ben Ayed; Amel Benammar Elgaaied
Journal:  Front Immunol       Date:  2018-02-23       Impact factor: 7.561

7.  PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.

Authors:  Xiaojia Huang; Xinhua Xie; Hua Wang; Xiangsheng Xiao; Lu Yang; Zhi Tian; Xiaofang Guo; Lijuan Zhang; Hailin Tang; Xiaoming Xie
Journal:  J Exp Clin Cancer Res       Date:  2017-09-15

Review 8.  Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment.

Authors:  Angelica Avagliano; Giuseppe Fiume; Alessandra Pelagalli; Gennaro Sanità; Maria Rosaria Ruocco; Stefania Montagnani; Alessandro Arcucci
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

Review 9.  Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications.

Authors:  Alice Indini; Francesco Grossi; Mario Mandalà; Daniela Taverna; Valentina Audrito
Journal:  Biomedicines       Date:  2021-05-26

10.  pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma.

Authors:  Olga Kuchuk; Alessandra Tuccitto; Davide Citterio; Veronica Huber; Chiara Camisaschi; Massimo Milione; Barbara Vergani; Antonello Villa; Malcolm Ronald Alison; Simone Carradori; Claudiu T Supuran; Licia Rivoltini; Chiara Castelli; Vincenzo Mazzaferro
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.